Form 8-K · Item 4.02 · Non-reliance
GT Biopharma, Inc.: non-reliance on previously issued financial statements
GT Biopharma, Inc. reported in a Form 8-K filed March 2, 2026, that on March 1, 2026, its audit committee concluded that previously issued financial statements should no longer be relied upon: the quarterly periods ended June 30, 2025, and September 30, 2025.
In the filing's words
on March 1, 2026, the audit committee of the Company’s board of directors, after discussion with the Company’s management and Weinberg, concluded that this resulted in an error in the Company’s interim quarterly financial statements as originally reported
in the Company’s Quarterly Reports on Form 10-Q for the quarterly periods ended June 30, 2025, and September 30, 2025, which may no longer be relied upon.
Verbatim from sec.gov, Item 4.02 (Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review). We quote the filing; we do not characterize it.
| Company | GT Biopharma, Inc. |
|---|---|
| Ticker | GTBP |
| Form and item | 8-K, Item 4.02 |
| Filed with the SEC | March 2, 2026 |
| Statements no longer relied upon |
|
| Concluded by | audit committee |
| Date of the conclusion | March 1, 2026 |
| Discussed with the accountant | not stated |
| Accession number | 0001493152-26-008442 |
| SEC CIK | 0000109657 |
GT Biopharma, Inc. reported under Form 8-K Item 4.02 (Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review), filed March 2, 2026. The filing's own words are quoted above.
Sources
- sec.gov · SEC filing, Form 8-K, Item 4.02 · accessed 2026-10-24
More: all non-reliance and restatements · Something wrong? Send a correction with the primary source.